GlassScriptPhysician profile
Neena Bhatti
NPI 1114923505
$30,625.08
in general payments reported to CMS, 2019-2025
39 companies · $2,370 in 2025
The $2,370 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,069 · 2020: $5,103 · 2021: $11K · 2022: $3,745 · 2023: $3,795 · 2024: $2,767 · 2025: $2,370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,712 · Education: $196 · Consulting Fee: $24.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,711.80 |
| Education | $195.93 |
| Consulting Fee | $24.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $7,208.47 | 2019-2022 | |
| Glaxosmithkline, LLC. | $5,473.78 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $3,604.90 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Genzyme Corporation | $2,359.06 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,674.89 | 2019-2025 | Dupixent |
| Pfizer INC. | $1,333.97 | 2019-2025 | |
| Genentech USA, INC. | $1,008.96 | 2019-2025 | Xolair |
| Grifols USA, LLC | $974.38 | 2019-2025 | Xembify, Prolastin-C Liquid |
| Csl Behring | $863.92 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Takeda Pharmaceuticals U.S.A., INC. | $788.11 | 2020-2025 | Cuvitru, Takhzyro |
| Optinose US, INC. | $697.62 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $662.46 | 2019-2025 | |
| Abbvie INC. | $596.68 | 2022-2024 | Rinvoq |
| Amgen INC. | $568.75 | 2021-2025 | Tezspire |
| Sanofi-Aventis U.S. LLC | $385.82 | 2021-2024 |
Show all 38 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neena Bhatti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.